AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PM (patients who listened to music before the operation)
Number of subjects: 0
Study 32829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Group PM
Number of subjects: 0
Study 32829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CM (patients who listened to music both before and during the operation)
Number of subjects: 0
Study 32829925 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CM
Number of subjects: 0
Study 32829925 — intervention group
Group type: COMPARATOR
Intervention: Group NM (Non‐Music, control group)
Number of subjects: 0
Study 33347024 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (300 mg/day)
Number of subjects: 72
Study 33347024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 32421444 — intervention group
Group type: COMPARATOR
Intervention: Standard anthracycline plus ifosfamide neoadjuvant chemotherapy (A+I)
Number of subjects: 287
Study 32421444 — intervention group
Group type: EXPERIMENTAL
Intervention: Histology-tailored neoadjuvant chemotherapy (HT)
Number of subjects: 287
Study 35656979 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Number of subjects: 5390
Study 35656979 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic Acid (Aspirin)
Number of subjects: 5390
Study 34087823 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga-based cognitive behavioral therapy (Y-CBT)
Number of subjects: 58
Study 34087823 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 58
Study 32006002 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGM‐CSF gel
Number of subjects: 62
Study 36057608 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BuNa)
Number of subjects: 100
Study 36057608 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 100
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA clearance during nCRT
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of acquired mutations in ctDNA
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA clearance
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score predictive model combining ctDNA and MRI
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA alone
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI alone
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of potential CRC driver genes in ctDNA after nCRT
Number of subjects: 119
Study 34464382 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable driver mutations and positive HR_feature after surgery
Number of subjects: 119
Study 32577902 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 81
Study 32577902 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative controls
Number of subjects: 81
Study 36191231 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital musical rhythm training
Number of subjects: 0
Study 36191231 — intervention group
Group type: COMPARATOR
Intervention: Word search (control)
Number of subjects: 0
Study 33950073 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing associated with cognitive behavioral therapy (CBT)
Number of subjects: 329
Study 33950073 — intervention group
Group type: COMPARATOR
Intervention: Control group (CBT only)
Number of subjects: 329
Study 33950073 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing group
Number of subjects: 329
Study 33950073 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 329
Study 32439819 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower eGFR
Number of subjects: 0
Study 32439819 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher UACR
Number of subjects: 0
Study 36172209 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing support for the implementation of BCP-VAMOS
Number of subjects: 0
Study 36172209 — intervention group
Group type: COMPARATOR
Intervention: Traditional didactic approach (control group)
Number of subjects: 0
Study 32833291 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehend, Cope, and Connect (CCC) intervention delivered face-to-face
Number of subjects: 23
Study 35303462 — intervention group
Group type: EXPERIMENTAL
Intervention: CBR plus facility-based care
Number of subjects: 166
Study 35303462 — intervention group
Group type: COMPARATOR
Intervention: Facility-based care
Number of subjects: 166
Study 32241214 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (free eye exam provided)
Number of subjects: 1454
Study 32241214 — intervention group
Group type: EXPERIMENTAL
Intervention: Education group (free eye exam provided)
Number of subjects: 1454
Study 32241214 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive and education group (free eye exam provided)
Number of subjects: 1454
Study 32241214 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1454
Study 36273490 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination (5 × 10^10 viral particles)
Number of subjects: 50
Study 34302893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) levels during chemoradiation therapy (CRT)
Number of subjects: 225
Study 34302893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) levels during CRT
Number of subjects: 225
Study 34302893 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) levels before treatment
Number of subjects: 225
Study 34114429 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (100mg BD for 14 days, then 150mg BD for 7 days, and 200mg BD for 21 days)
Number of subjects: 57
Study 34114429 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 34114429 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 57
Study 33587659 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen
Number of subjects: 21005
Study 36191401 — intervention group
Group type: EXPERIMENTAL
Intervention: Anteromedial portal (AMP) technique
Number of subjects: 33
Study 36191401 — intervention group
Group type: COMPARATOR
Intervention: Transtibial (TT) technique
Number of subjects: 33
Study 33640458 — intervention group
Group type: EXPERIMENTAL
Intervention: External cold and vibration (Buzzy®) applied for 30 seconds before and during vaccination
Number of subjects: 90
Study 33640458 — intervention group
Group type: COMPARATOR
Intervention: No intervention during vaccination
Number of subjects: 90
Study 32250066 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day preparation using PEG 3350 (4 g/kg/day) + bisacodyl
Number of subjects: 72
Study 32250066 — intervention group
Group type: COMPARATOR
Intervention: 2-day preparation using PEG 3350 (2 g/kg/day) + bisacodyl
Number of subjects: 72
Study 35554590 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (initially 10 mg, increased to 20 mg after 1 week if tolerated)
Number of subjects: 37
Study 35554590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 33226002 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 1596
Study 33226002 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 1596
Study 34511307 — intervention group
Group type: COMPARATOR
Intervention: Single vision contact lenses
Number of subjects: 24
Study 34511307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low add multifocal soft contact lenses
Number of subjects: 24
Study 34511307 — intervention group
Group type: EXPERIMENTAL
Intervention: High add multifocal soft contact lenses
Number of subjects: 24
Study 33793700 — intervention group
Group type: COMPARATOR
Intervention: Hysterosalpingography (HSG)
Number of subjects: 56
Study 33793700 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterosalpingo-contrast ultrasonography (HyCoUs)
Number of subjects: 56
Study 35880283 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 150
Study 35880283 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple acupuncture
Number of subjects: 150
Study 35880283 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine treatment)
Number of subjects: 150
Study 34014982 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual active-ingredient long-lasting insecticidal nets (LLINs) combining chlorfenapyr or pyriproxifen with alpha-cypermethrin
Number of subjects: 10807
Study 34014982 — intervention group
Group type: COMPARATOR
Intervention: Standard pyrethroid LLINs
Number of subjects: 10807
Study 34014982 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-cypermethrin
Number of subjects: 10807
Study 34014982 — intervention group
Group type: EXPERIMENTAL
Intervention: PBO pre-exposure followed by alpha-cypermethrin
Number of subjects: 10807
Study 34014982 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 10807
Study 32956890 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB (Erector Spinae Plane Block)
Number of subjects: 90
Study 32956890 — intervention group
Group type: EXPERIMENTAL
Intervention: mTLIP (Modified-Thoracolumbar Interfascial Plane Block)
Number of subjects: 90
Study 32956890 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 32956890 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB
Number of subjects: 90
Study 32956890 — intervention group
Group type: EXPERIMENTAL
Intervention: mTLIP
Number of subjects: 90
Study 32956890 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 33629239 — intervention group
Group type: EXPERIMENTAL
Intervention: Unisol-CV (UCV)
Number of subjects: 0
Study 33629239 — intervention group
Group type: COMPARATOR
Intervention: Phosphate-buffered saline (PBS)
Number of subjects: 0
Study 33629239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulbecco's Modified Eagle's Medium: Nutrient Mixture F-12 (DMEM)
Number of subjects: 0
Study 33629239 — intervention group
Group type: EXPERIMENTAL
Intervention: X-VIVO
Number of subjects: 0
Study 33675695 — intervention group
Group type: EXPERIMENTAL
Intervention: EDIFY interventions
Number of subjects: 100
Study 33675695 — intervention group
Group type: COMPARATOR
Intervention: Standard care (nonintervention group)
Number of subjects: 100
Study 35896519 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based therapy for insomnia (MBTI)
Number of subjects: 113
Study 35896519 — intervention group
Group type: COMPARATOR
Intervention: Sleep hygiene, education, and exercise programme (SHEEP)
Number of subjects: 113
Study 33691304 — intervention group
Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 9013
Study 33691304 — intervention group
Group type: EXPERIMENTAL
Intervention: New diabetes
Number of subjects: 9013
Study 33691304 — intervention group
Group type: COMPARATOR
Intervention: BMS or DES
Number of subjects: 9013
Study 32745945 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss condition of the computerized task
Number of subjects: 364
Study 32745945 — intervention group
Group type: COMPARATOR
Intervention: Control condition of the computerized task
Number of subjects: 364
Study 32745945 — intervention group
Group type: EXPERIMENTAL
Intervention: Craving
Number of subjects: 364
Study 32745945 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol misuse
Number of subjects: 364
Study 32745945 — intervention group
Group type: EXPERIMENTAL
Intervention: Gambling severity
Number of subjects: 364
Study 32223585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial therapy (three 45‐min sessions over a 3‐week period)
Number of subjects: 14
Study 34030720 — intervention group
Group type: EXPERIMENTAL
Intervention: Exoskeleton-assisted walking (EAW)
Number of subjects: 18
Study 34030720 — intervention group
Group type: COMPARATOR
Intervention: Conventional training
Number of subjects: 18
Study 32813935 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral epinephrine
Number of subjects: 30
Study 32813935 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (control)
Number of subjects: 30
Study 35132871 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline neutrophil-lymphocyte ratio (NLR; ≥3.8)
Number of subjects: 756
Study 33276518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral resveratrol supplementation for 4 days
Number of subjects: 9
Study 33276518 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 4 days
Number of subjects: 9
Study 33276518 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral resveratrol supplementation
Number of subjects: 9
Study 33276518 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 9
Study 34097301 — intervention group
Group type: EXPERIMENTAL
Intervention: Stay Active at Home (SAaH) reablement training program for homecare staff
Number of subjects: 264
Study 34097301 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control group)
Number of subjects: 264
Study 33032338 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplitude panning
Number of subjects: 27
Study 33032338 — intervention group
Group type: COMPARATOR
Intervention: Physical sources
Number of subjects: 27
Study 33032338 — intervention group
Group type: COMPARATOR
Intervention: Panned sources
Number of subjects: 27
Study 33032338 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall localization task
Number of subjects: 27
Study 33032338 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and elevation errors
Number of subjects: 27
Study 35977462 — intervention group
Group type: EXPERIMENTAL
Intervention: Sotrovimab (monoclonal antibody for SARS-CoV-2 infection)
Number of subjects: 0
Study 35977462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34008769 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic exercises for pain relief
Number of subjects: 23
Study 34008769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no isotonic exercises)
Number of subjects: 23
Study 35618959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting overall survival (OS)
Number of subjects: 280
Study 35618959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting OS
Number of subjects: 280
Study 35618959 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram
Number of subjects: 280
Study 34285713 — intervention group
Group type: EXPERIMENTAL
Intervention: COC with GR blockade (mifepristone; 80.0 mg/kg; po)
Number of subjects: 24
Study 34285713 — intervention group
Group type: EXPERIMENTAL
Intervention: COC with MR blockade (spironolactone; 0.25 mg/kg; po)
Number of subjects: 24
Study 34285713 — intervention group
Group type: COMPARATOR
Intervention: COC (1.0 μg ethinylestradiol and 5.0 μg levonorgestrel; po)
Number of subjects: 24
Study 34285713 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (po)
Number of subjects: 24
Study 35101832 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus clausii UBBC07 (oral suspension of 2 billion spores twice daily for 30 days)
Number of subjects: 46
Study 35101832 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard treatment)
Number of subjects: 46
Study 34838105 — intervention group
Group type: EXPERIMENTAL
Intervention: SPIN-SELF Program (group-based intervention delivery format)
Number of subjects: 40
Study 34838105 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 40
Study 33025883 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (DC)
Number of subjects: 51
Study 33025883 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC)
Number of subjects: 51
Study 33025883 — intervention group
Group type: EXPERIMENTAL
Intervention: Decaffeinated coffee (DC) in hyperuricaemic participants
Number of subjects: 51
Study 33025883 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (CC) in non-hyperuricaemic participants
Number of subjects: 51
Study 36251165 — intervention group
Group type: EXPERIMENTAL
Intervention: Rencofilstat (RCF) 225-mg soft gelatin capsules with high-fat meal
Number of subjects: 44
Study 36251165 — intervention group
Group type: COMPARATOR
Intervention: Rencofilstat (RCF) 225-mg soft gelatin capsules in fasted condition
Number of subjects: 44
Study 36251165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 44
Study 36251165 — intervention group
Group type: COMPARATOR
Intervention: Fasted group
Number of subjects: 44
Study 36251165 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal group
Number of subjects: 44
Study 32543929 — intervention group
Group type: EXPERIMENTAL
Intervention: PA + C group (MoVo‐work intervention with psychological coaching and PA component)
Number of subjects: 213
Study 36093397 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of core stability training, 3 times/week
Number of subjects: 31
Study 36093397 — intervention group
Group type: COMPARATOR
Intervention: AIS group (no intervention)
Number of subjects: 31
Study 36093397 — intervention group
Group type: COMPARATOR
Intervention: Normal group (no intervention)
Number of subjects: 31
Study 34389569 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote photoplethysmography imaging (rPPG) system measurements of heart rate (HR), respiratory rate (RR), and oxygen saturation (SpO 2)
Number of subjects: 1045
Study 34389569 — intervention group
Group type: COMPARATOR
Intervention: Standard acquisition system measurements of heart rate (HR), respiratory rate (RR), and oxygen saturation (SpO 2)
Number of subjects: 1045
Study 32415365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV‐TXA) 1 g before incision and 3 h later
Number of subjects: 122
Study 32415365 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 122
Study 32415365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV‐TXA)
Number of subjects: 122
Study 32415365 — intervention group
Group type: EXPERIMENTAL
Intervention: IV‐TXA (meta-analysis)
Number of subjects: 122
Study 34022863 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid postoperative protocol (standardized non-opioid analgesic prescription, limited rescue opioid prescription, patient education infographic)
Number of subjects: 200
Study 34022863 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care (treating surgeons’ pre-trial postoperative analgesic regimen)
Number of subjects: 200
Study 34022863 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid postoperative protocol
Number of subjects: 200
Study 34022863 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 200
Study 32808504 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary debulking surgery (PDS) followed by 6 cycles of standard adjuvant chemotherapy
Number of subjects: 456
Study 32808504 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy followed by interval debulking surgery (NACT‐IDS) with 3 cycles of NACT and subsequently 3 cycles of adjuvant chemotherapy
Number of subjects: 456
Study 35485864 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F‐fludarabine (18F‐FLUDA) PET/CT
Number of subjects: 31
Study 35485864 — intervention group
Group type: COMPARATOR
Intervention: 11C‐MET
Number of subjects: 31
Study 33667227 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) + Sildenafil (50 mg)
Number of subjects: 129
Study 33667227 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (0.5 mg) + Buspirone (10 mg)
Number of subjects: 129
Study 33667227 — intervention group
Group type: COMPARATOR
Intervention: Matching Placebos
Number of subjects: 129
Study 32991207 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquatic Therapy Group (ATG)
Number of subjects: 20
Study 32991207 — intervention group
Group type: COMPARATOR
Intervention: Conventional Training Group (CTG)
Number of subjects: 20
Study 34049943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab (700 mg intravenously at 4-week intervals for 12 weeks)
Number of subjects: 40
Study 34049943 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenously at 4-week intervals for 12 weeks)
Number of subjects: 40
Study 34049943 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Number of subjects: 40
Study 34049943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33112025 — intervention group
Group type: EXPERIMENTAL
Intervention: Eversion group (n = 52)
Number of subjects: 104
Study 33112025 — intervention group
Group type: COMPARATOR
Intervention: Retraction group (n = 52)
Number of subjects: 104
Study 33112025 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 104
Study 33129156 — intervention group
Group type: EXPERIMENTAL
Intervention: Worrisome contemplation (n = 60)
Number of subjects: 245
Study 33129156 — intervention group
Group type: COMPARATOR
Intervention: Objective contemplation (n = 63)
Number of subjects: 245
Study 33129156 — intervention group
Group type: COMPARATOR
Intervention: Diaphragmatic breathing task (n = 62)
Number of subjects: 245
Study 33075844 — intervention group
Group type: EXPERIMENTAL
Intervention: 81-mg daily aspirin
Number of subjects: 1228
Study 33075844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study 33959770 — intervention group
Group type: EXPERIMENTAL
Intervention: Single response assessment
Number of subjects: 79
Study 33959770 — intervention group
Group type: COMPARATOR
Intervention: International Myeloma Working Group criteria
Number of subjects: 79
Study 33990483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree Pose‐added exercise group (30‐min conventional exercise + 2‐min Tree Pose/d for 12 wks)
Number of subjects: 32
Study 33990483 — intervention group
Group type: COMPARATOR
Intervention: Conservative exercise group (30 mins/d for 12 wks)
Number of subjects: 32
Study 33990483 — intervention group
Group type: EXPERIMENTAL
Intervention: Tree Pose‐added exercise group
Number of subjects: 32
Study 33990483 — intervention group
Group type: COMPARATOR
Intervention: Conservative exercise group
Number of subjects: 32
Study 34511166 — intervention group
Group type: EXPERIMENTAL
Intervention: mNGF treatment
Number of subjects: 60